Tarin D, 1985, Clinical and experimental studies on the biology of metastasis.Biochimica et Biophysica Acta,780, 227–235.
Fidler IJ, 1990, Critical factors in the biology of human cancer metastasis: twenty-eight GHA Clowes memorial award lecture.Cancer Research,50, 6130–6138.
Tryggvason K, Hoyhtya M and Salo T, 1987, Proteolytic degradation of extracellular matrix in tumor invasion.Biochimica et Biophysica Acta,907, 191–207.
Timpl R, 1989, Structure and biological activity of basement membrane proteins.European Journal of Biochemistry,180, 487–502.
Duffy MJ, 1990, Plasminogen activators and cancer.Blood Coagulation and Fibrinolysis, 1, 681–687.
Testa JE and Quigley JP, 1990, The role of urokinase-type plasminogen activator in aggressive tumor cell behavior.Cancer Metastasis Reviews,9, 353–367.
Stoppelli MP, Corti A, Soffientini A, Cassani G, Blasi F and Assoian RK, 1985, Differentiation enhanced binding of the amino terminal fragment of human urokinase plasminogen activator to a specific receptor on 11937 monocytes.Proceedings of the National Academy of Sciences, USA,82, 4939–4943.
Vassali J-D, Baccino D and Belin D, 1985, A cellular binding site for the Mr 55,000 form of the human plasminogen activator.Journal of Cell Biology,100, 86–92.
Ossowski L, 1988,In vivo invasion of modified chorioallantoic membrane by tumor cells: the role of cell surface-bound urokinase.Journal of Cell Biology,107, 2437–2445.
Sloane BF, Moin K, Krepela E and Rozhin J, 1990, Cathepsin B and its endogenous inhibitors: the role in tumor malignancy.Cancer Metastasis Reviews,9, 333–352.
Nishimura Y, Kawabata T and Kato K, 1988, Identification of latent procathepsin B and L in microsomal lumen.Archives of Biochemistry and Biophysics,261, 64–71.
Hara K, Kominami E and Katunuma N, 1988, Effect of proteinase inhibitors on intracellular processing of cathepsin B, H and L in rat macrophages.FEBS Letters,231, 229–231.
Eeckhout Y and Vaes G, 1977, Further studies on the activation of procollagenase, the latent precursor of bone collagenase. Effects of lysosomal cathepsin B, plasmin and kallikrein and spontaneous activation.Biochemical Journal,36, 1555–1563.
Kobayashi H, Schmitt M, Goretzki L, Chuchowolski N, Calvete J, Kramer M, Gunzler WA, Janicke F and Graeff H, 1991, Cathepsin B efficiently activates the soluble and the tumor cell receptor-bound form of the proenzyme urokinase-type plasminogen activator (pro-uPA).Journal of Biological Chemistry, 266, 5147–5152.
Sloane BF, Rozhin J, Johnson K, Taylor H, Crissman J and Honn KV, 1986, Cathepsin B: association with plasma membrane in metastatic tumors.Proceedings of the National Academy of Sciences, USA,83, 2483–2487.
Keren Z and LeGrue SJ, 1988, Identification of cell surface cathepsin B-like activity on murine melanomas and fibrosarcomas: modulation by butanol extraction.Cancer Research,48, 1416–1421.
Pagano M, Dalet-Fumeron V and Engler R, 1989, The glycosylation state of the precursors of the cathepsin-like proteinase from human malignant as citic fluid: possible implication in the secretory pathways of these proenzymes. Cancer Letters, 45, 13–19.
Westley B and Rochefort H, 1980, A secreted glycoprotein induced by estrogen in human breast cancer cell lines.Cell,20, 52–362.
Vignon F, Capony F, Chambon M, Freiss G, Garcia M, and Rochefort H, 1986, Autocrine growth stimulation on the MCF7 breast cancer cells by the estrogen-regulated 52K protein.Endocrinology,118, 1517–1545.
Briozzo P, Morisset M, Capony F, Rougeot C and Rochefort H, 1988,In vitro degradation of extracellular matrix with Mr 52,000 cathepsin D secreted by breast cancer cells.Cancer Research,48, 3688–3692.
Rochefort H, Capony F and Garcia M, 1990, Cathepsin D: a protease involved in breast cancer metastasis.Cancer Metastasis Reviews,9, 321–331.
Capony F, Rougeot P, Montcourrier P, Cavailles V, Salazar G and Rochefort H, 1989, Increased secretion, altered processing, and glycosylation of proca thepsin D in human mammary cancer cells.Cancer Research,49, 3904–3909.
Murphy G, Reynolds JJ and Hembry RM, 1989, Metalloproteases and cancer invasion and metastasis.International Journal of Cancer,44, 757–760.
Liotta L, Tryggvason K, Garbisa S, Gehron-Ribey P and Abe S, 1981, Partial purification and characterization of a neutral protease which cleaves type IV collagen.Biochemistry,20, 100–104.
Wilhelm SM, Collier IE, Marmer BL, Eisen AZ, Grant GA and Goldberg GI, 1989, SV40 transformed human lung fibroblasts secrete a 92 kDa type IV collagenase which is identical to that secreted by normal human macrophages.Journal of Biological Chemistry,264, 17213–17221.
Kato Y, Ogawa K, Yamomoto S, Abe S, Kishi J and Hayakawa T, 1990, A novel TIMP-insensitive type IV collagen-degrading metalloprotease from murine metastatic sarcoma cells.FEBS Letters,268, 39–42.
McDonnell S and Matrisian LM, 1990, Stromelysin in tumor progression and metastasis.Cancer Metastasis Reviews,9, 305–319.
Basset P, Bellocq JP, Wolf C, Stoll I, Hutin P, Limacher J, Podhajeer O, Chenard M, Rio M and Chambon P, 1990, A novel metalloprotease gene specifically expressed in stromal cells of breast carcinomas.Nature,348, 699–704.
Saksela O, 1985, Plasminogen activation and regulation of pericellular proteolysis.Biochimica et Biophysica Acta,823, 35–65.
Duffy MJ, 1987, Do proteases play a role in cancer invasion and metastasis?European Journal of Cancer and Clinical Oncology,23, 583–589.
Wang BS, McLoughlin GA, Richie JP and Mannick JA, 1980, Correlation of the production of plasminogen activator with tumor metastasis in B16 mouse melanoma cell lines.Cancer Research,40, 288–292.
Sloane BF, Dunn JR and Horn KV, 1981, Lysosomal cathepsin B: correlation with metastatic potential.Science,212, 1151–1153.
Liotta L, Tryggvason K, Garbisa S, Hart I, Foltz C and Shafie S, 1980, Metastatic potential correlates with enzymatic degradation of basement membrane collagen.Nature,284, 67–68.
Qian F, Bajkowski As, Steiner DF, Chan SJ and Frankfater A, 1989, Expression of 5 cathepsins in murine melanomas of varying metastatic potential and normal tissue.Cancer Research,49, 4870–4875.
Carlsen SA, Ramshaw IA and Warrington RC, 1984, Involvement of plasminogen activator production with tumor metastasis in a rat model.Cancer Research,44, 3012–3016.
Eisenbach L, Segal S and Feldman M, 1985, Proteolytic enzymes in tumor metastasis. 1. Plasminogen activator in clones of Lewis lung carcinoma and T10 sarcoma.Journal of the National Cancer Institute,74, 77–85.
Tarin D, Hoyt BJ and Evan DJ, 1982, Correlation of collagenase secretion with metastatic colonization in naturally-occurring murine mammary tumours.British Journal of Cancer,46, 266–278.
Sekiya S, Oosaki T and Suzuki N, 1985, Invasion potential of human choriocarcinoma cell lines and the role of lytic enzymes.Gynecology and Oncology,22, 324–333.
Koppel P, Baici A, Keist R, Matzku S and Keller R, 1984, Cathepsin B-like proteinase as a marker for metastatic tumor cell variants.Experimental Cell Biology,52, 293–299.
Zucker S, Beck G, Distefano JF and Lysik RM, 1985, Role of different cell proteinases in cancer invasion and cytolysis.British Journal of Cancer,52, 223–232.
Lowe FC and Issacs JT, 1984, Biochemical methods for predicting metastatic ability of prostatic cancer utilizing the Dunning R-3327 rat prostatic adenocar cinoma system as a model.Cancer Research,44, 744–752.
Bernhard EJ, Muschel RJ and Hughes EN, 1990, Mr 92,000 gelatinase release correlates with the metastatic phenotype in transformed rat embryo cells.Cancer Research,50, 3872–3877.
Nakajima M, Irimura T and Nicolson GL, 1988, Heparanases and tumor metastasis.Journal of Cell Biochemistry,36, 157–167.
Garbisa S, Pozzatti R, Muschel R, Saffiotti U, Ballin M and Goldfarb R, 1987, Secretion of type IV collagenolytic protease and metastatic phenotype: induction by transfection with c-Ha-ras but not c-Ha-ras plus Ad2-Ela.Cancer Research,47, 1523–1528.
Halaka A, Bunning R, Bird CC, Gibson M and Reynolds JJ, 1983, Production of collagenase and inhibitor TIMP by intracranial tumors and durain vitro.Journal of Neurosurgery,59, 461–466.
Hicks NJ, Ward RV and Reynolds JJ, 1984, A fibrosarcoma model derived from mouse embryo cells: growth properties and secretion of collagenase and metalloproteinase inhibitor (TIMP) by tumour cell lines.International Journal of Cancer,33, 835–844.
Khokha R, Waterhouse P, Yagel S, Lala PK, Overall CM, Norton G and Denhardt DT, 1989, Antisense RNA-induced reduction in murine TIMP level confers oncogenicity on Swiss 3T3 cells.Science,243, 947–950
Khokha R and Denhardt DT, 1989, Matrix metalloproteinases and tissue inhibitors of metalloproteinases: a review of their role in tumorigenesis and tissue invasion.Invasion and Metastasis,9, 391–405.
Rozhin J, Gomez AP, Ziegler GH, Nelson KK, Chang YS, Fong D, Onoda J, Honn KV and Sloane BF, 1990, Cathepsin B to cysteine proteinase inhibitor balance in metastatic cell subpopulations isolated from murine tumors.Cancer Research,50, 6278–6284.
Neri A, Bohoslawec O, Anderson TD and Tokes ZA, 1991, Differential release of active proteinase inhibitors by two rat mammary adenocarcinoma variants possessing different metastatic potential.Cancer Research,51, 1318–1325.
Lah TT, Clifford JL, Helmer KM, Day NA, Moin K, Honn KV, Crissman JD and Sloane BF, 1989, Inhibitory properties of low molecular mass cysteine proteinase inhibitors from human sarcoma.Biochimica et Biophysica Acta,993, 63–73.
Janicke F, Schmitt M and Graeff H, 1991, Clinical relevance of the urokinase-type and tissue-type plasminogen activators and their type 1 inhibition in breast cancer.Seminars in Thrombosis and Hemostasis,17, 302–312.
Reilly D, Andreasen P and Duffy MJ, 1989, Studies on plasminogen activator inhibitor PAI-1 in human breast cancer.Biochemical Society Transactions,17, 609.
Mignatti P, Robbins E and Rifkin DB, 1986, Tumor invasion through the human amniotic membrane: requirement for a proteinase cascade.Cell,47, 487–498.
Cajot JF, Bamat J, Bergonzelli GE, Kruithof E, Medcalf RI, Tetuz J and Sordat B, 1990, Plasminogen activator inhibitor type 1 is a potent natural inhibitor of extracellular matrix degradation by fibrosarcoma and colon carcinoma cells.Proceedings of the National Academy of Sciences, USA,87, 6939–6943.
Baker MS, Bleakley P, Woodrow GC and Doe WF, 1990, Inhibition of cancer cell urokinase by its specific inhibitor PAI-2 and subsequent effects on extracellular matrix degradation.Cancer Research,50, 4676–4684.
DeClerck YA, Yean T-D, Chan D, Shimada H and Langley KE, 1991, Inhibition of tumor invasion of smooth muscle cell layers by recombinant human metalloproteinase inhibitor.Cancer Research,51, 2151–2157.
Schultz RM, Silberman S, Persky B, Bajowski A and Carmichael D, 1988, Inhibition by human recombinant tissue inhibitor of metalloproteinases of human amnion invasion and lung colonization by murine B16-F1O melanoma cells.Cancer Research,48, 5539–5545.
Alvarez OA, Carmichael DF and DeClerck YA, 1990, Inhibition of collagenolytic ;activity and metastasis of tumor cells by a recombinant human tissue inhibitor of metalloproteinases.Journal of the National Cancer Institute,82, 589–595.
Ossowski L and Reich E, 1983, Antibodies to plasminogen activator inhibit human tumor metastasis.Cell,35, 611–619.
Ossowski L, Russo-Payne H and Wilson EL, 1991, Inhibition of urokinase-type plasminogen activator by antibodies: the effect on dissemination of a human tumor in the nude mouse model.Cancer Research,51, 274–281.
Hearing VJ, Law L, Corti A, Appella E and Blasi F, 1988, Modulation of metastatic potential by cell surface urokinase of murine melanoma cells.Cancer Research,48, 1270–1278.
Hoyhtya M, Hujanen E and Turpeenniemi-Hujanen T, 1990, Modulation of type IV collagenase and invasive behaviour of metastatic melanoma (A2058) cells in vitro by monoclonal antibodies to type IV collagenase.International Journal of Cancer,46, 282–286.
Kodama Y and Tanaka T, 1978, Effect of urokinase on growth and metastasis of rabbit V2 carcinoma.Gann,69, 9–15.
Tanaka N, Ogawa H, Tanaka K, Kinjo M and Kohga S, 1981, Effects of tranexamic acid and urokinase on hematogenous metastases of Lewis lung carcinoma in mice.Invasion and Metastasis,1, 149–157.
Nierodzik ML, Plotkin A, Kajumo F and Karpatkin S, 1991, Thrombin stimulates tumor-platelet adhesionin vitro and metastasisin vitro.Journal of Clinical Investigations,87, 229–236.
Axelrod JH, Reich R and Miskin R, 1989, Expression of human recombinant plasminogen activator enhances invasion and experimental metastasis of H-ras-transformed NIH 3T3 cells.Molecular Cell Biology,9, 2133–2141.
Cajot J-F, Schleuning W-D, Medcalf RL, Bamat J, Tetuz J, Libermann L and Sordat B, 1989, Mouse L-cells expressing human prourokinase-type plasminogen activator: effects on extracellular matrix degradation and invasion.Journal of Cell Biology,109, 915–925.
Yu H and Schultz RM, 1990, Relationship between secreted urokinase plasminogen activator activity and metastatic potential in murine B16 cells transfected with human urokinase sense and antisense genes.Cancer Research,50, 7623–7633.
Garcia M, Derocq D, Pujol P and Rochefort H, 1990, Overexpression of transfected cathepsin D in transformed cells increases their malignant phenotype and metastatic potency.Oncogene,5, 1809–1814.
Skriver L, Larsson L, Kielberg V, Nielsen LS, Andresen PB, Kristensen P and Dano K, 1984, Immunocytochemical localisation of urokinase type plasminogen activator in Lewis lung carcinoma.Journal of Cell Biology,99, 753–758.
Kristensen P, Pyke C, Lund LR, Andreasen PA and Dano K, 1990, Plasminogen activator inhibitor type 1 in Lewis lung carcinoma.Histochemistry,93, 559–566.
Baici A, Gyger-Marazzi M and Strauli P, 1984, Extracellular cysteine proteinase and collagenases activities as a consequence of tumor-host interaction in the rabbit V2 carcinoma.Invasion and Metastasis,4, 13–27.
Koivunen E, Huhtala M-L and Stenman U-H, 1989, Human ovarian tumor-associated trypsin.Journal of Biological Chemistry,264, 14095–14099.
Kirchheimer JC, Wojta J, Christ G and Binder BR, 1987, Proliferation of a human epidermal tumor cell line by urokinase.FASEB Journal,1, 125–128.
Lyons RM, Keski-Oja J and Moses HL, 1988, Proteolytic activation of latent transforming growth factor-beta from fibroblast conditioned medium.Journal of Cell Biology,106, 1659–1665.
Ossowski L, Quigley JP and Reich E. Plasminogen-a necessary factor for cell migrationin vitro. In: Reich E, Rifkin DB, Shaw W, eds.Proteases and Biological Control. New York: Cold Spring Harbor Laboratory, 1975, pp. 901–913.
Gilbert LC and Gordon SG, 1983, Relationship between procoagulant activity and metastatic capacity of B16 mouse melanoma variants.Cancer Research,43, 536–540.
Day ED, Planinsek JA and Pressman D, 1959, Localisationin vivo of radioiodinated rat fibrinogen in the Murphy rat lymphosarcoma and in other transplantable rat tumors.Journal of the National Cancer Institute,22, 413–426.
Horn KV, Cavanaugh P and Evens C, 1982, Tumor cell-platelet aggregation: induced by cathepsin Blike proteinase and inhibited by prostacyclin.Science, 217, 540–542.
Sylven B, 1968, Cellular detachment by purified lysomal cathepsin B.European Journal of Cancer,4, 559–562.
Gross JL, Mosatelli D and Rifkin DB, 1983, Increased capillary endothelial protease activity in response to angiogenic stimuliin vitro.Proceedings of the National Academy of Sciences, USA,80, 2623–2627.
Gudewicz PW and Gilboa N, 1987, Human urokinase-type plasminogen activator stimulates chemotaxis of human neutrophils.Biochemistry and Biophysics Research Communications,147, 1176–1181.
Duffy MJ, O'Grady P, Devaney D, O'Siorain L, Fennelly JJand Lijnen HJ, 1988, Urokinase-plasminogen activator, a marker for aggressive breast cancers. Preliminary report.Cancer,62, 531–533.
Duffy MJ, Reilly D, O'Sullivan C, O'Higgins N, Fennelly JJ and Andreasen PA, 1990, Urokinase plasminogen activator, a new and independent prognostic marker in breast cancer.Cancer Research,50, 6827–6829.
Janicke F, Schmitt M, Hafter R, Holrieder A, Babic R, Ulm K, Gossner W and Graeff H, 1990, Urokinase-type plasminogen activator (u-PA) antigen is a predictor of early relapse in breast cancer.Fibrinolysis,4, 69–78.
Janicke F, Schmitt M, Ulm K, Gossner W and Graeff H, 1989, The urokinase-type plasminogen activator (u-PA) antigen is related to early relapse in breast cancer.Lancet,ii, 1049.
Duffy MJ, Reilly D, O'Sullivan C, O'Higgins N and Fennelly JJ, 1990, Urokinase plasminogen activator and prognosis in breast cancer.Lancet,335, 108.
Thorpe S, Rochefort H, Garcia M, Freiss G, Christensen IJ, Khalaf S, Paulucci F, Pau P, Rasmussen BB and Rose C, 1989, Association between high concentrations of Mr 52,000 cathepsin D and poor prognosis in primary human breast cancer.Cancer Research,49, 6008–6014.
Spyratos F, Brouillet JP, Defrenne A, Hacene K, Rouesse J, Maudelonde T, Brunet M, Andrieu C, Desplaces A and Rochefort H, 1989, Cathepsin D: an independent prognostic factor for metastasis of breast cancer.Lancet,ii, 1115–1118.
Tandon AK, Clarke GM, Chamness GC, Chirgwin J and McGuire WL, 1990, Cathepsin D and prognosis in breast cancer.New England Journal of Medicine,322, 297–302.
Henry JA, McCarthy AL, Angus B, Westley BR, May F, Nicholson S, Cairns J, Harris AL and Horne C, 1990, Prognostic significance of the estrogen regulated protein, cathepsin D, in breast cancer.Cancer,65, 265–271.
Daidone MG, Silvestrini R, D'Errico A, DiFronzo G, Benini E, Mancini AM, Garbisa S, Liotta L, Grigioni W, 1991, Laminin receptors, collagenase IV and prognosis in node negative breast cancer.International Journal of Cancer,48, 529–532.
Abramson M, Schilling RW, Huang C and Salome RG, 1975, Collagenase activity in epidermoid carcinoma of the oral cavity and larynx.Annals of Otololaryngology,84, 158–163.
Muller D, Breathnach R, Engelmann A, Millon R, Bronner G, Flesch H, Dumont P, Eber M and Abecassis J, 1991, Expression of collagenase-related metalloproteinase genes in human lung or head or neck tumours.International Journal of Cancer,48, 550–556.
Oka T, Ishida T, Nishino T and Sugimachi K, 1991, Immunohistochemical or urokinase-type plasminogen activator in primary and metastatic tumors of pulmonary adenocarcinoma.Cancer Research,51, 3522–3525.
Sappino A-P, Belin D, Huarte J, Hirschel-Scholz S, Saurat JH and Vassalli J-D, 1991, Differential protease expression by cutaneous squamous and basal cell carcinomas.Journal of Clinical Investigations,88, 1073–1079.
Duffy MJ, O'Grady P, Devaney D, O'Siorain L, Fennelly JJ and Lijnen R, 1988, Tissue-type plasminogen activator, a new prognostic marker in breast cancer.Cancer Research,48, 1348–1349.
Duffy MJ, O'Grady P, Simon J, Rose M and Lijnen HR, 1986, Tissue-type plasminogen activator in breast cancer: relationship with estradiol and progesterone receptors.Journal of the National Cancer Institute,77, 621–623.